Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Neobetacell

Financiado

Cerrado

Neogenesis of new functional Beta Cells through Modulation of Neurogenin 3 Expre...

Neogenesis of new functional Beta Cells through Modulation of Neurogenin 3 Expression to provide Regenerative Therapy for Diabetes Patients Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood sugar levels with increased risk of cardiovascular complications. The currently available therapy for type 1 diabetes (TIDM) consists of daily injec... ver más

30/09/2021

VUB

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

VRIJE UNIVERSITEIT BRUSSEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-09-30

ERC-StG-2015: ERC Starting Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

VUB

1.50M€ | Lider

FELGUERA CONSTRUCCIONES MECA...

Proyectos interesantes

VANGUARD

Medical Technol...

Biotechnology

7M€ Cerrado

Micro Pancreas

Medical Technol...

Biotechnology

4M€ Cerrado

EEBB-I-12-04567

Medical Technol...

Regenerative Me...

6K€ Cerrado

SAF2008-02469

Medical Technol...

Regenerative Me...

146K€ Cerrado

DiogenX

Medical Technol...

Data Science

6M€ Cerrado

Merlin

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2016-09-01
Fecha Fin: 2021-09-30

Líder del proyecto

VRIJE UNIVERSITEIT BRUSSEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood sugar levels with increased risk of cardiovascular complications. The currently available therapy for type 1 diabetes (TIDM) consists of daily injections of exogenous insulin in order to delay disease progression. However, these treatments do not provide a real cure since long-term secondary complications cannot be avoided. As TIDM is characterized by the highly specific immune-mediated destruction of one cell type, this disease represents a particularly ideal candidate for cell replacement therapy. Transplantation of human islets, isolated from cadaveric donor pancreas, potentially represents a genuine cure for TIDM but is limited by a shortage of transplantable islets. In the current application I will create an unprecedented humanized mouse model to test pharmacological therapies for diabetes. In a first step I will study the actions of Geminin on the regulation of the pro-endocrine transcription factor Neurogenin3 during mouse and human development and postnatal beta cell regeneration from the exocrine cells of the pancreas. These experiments will provide tools to control Neurogenin3 expression and thus endocrine cell differentiation in the human pancreas. Using the knowledge gained from in vivo mouse studies, I will create a novel clinically relevant humanized mouse model. I will use this model to develop a cytokine-based treatment to convert human acinar cells to functional beta-like cells in a Neurogenin3 dependent way. Finally, I will design a strategy to deliver the pro-endocrine treatment in a cell-specific manner. The humanized model will serve as a unique platform to test treatment for human diabetes in the pre-clinical phase. This project utilizes a multidisciplinary approach to develop a strategy based on pharmacological treatment rather than cell therapy, paving the way for clinical application.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores